Beta-CrossLaps, Serum
Use
The Beta-CrossLaps (B-CTx) test is useful for monitoring antiresorptive therapies such as bisphosphonates and hormone replacement therapy in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia. It serves as an adjunct in diagnosing conditions associated with increased bone turnover. Unbalanced bone turnover is also found in age-related and postmenopausal osteopenia and osteoporosis.
Special Instructions
Not provided.
Limitations
Reduced kidney function may lead to reduced urinary excretion of beta-C-terminal telopeptide (CTx), resulting in an increased apparent serum beta-CTx concentration. The presence of antibodies to mouse or other animal antibodies, including heterophile antibodies, and antibodies to streptavidin or ruthenium may interfere with assay results. Biotin supplements up to 1200 ng/mL do not interfere with this assay.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
Beta-CrossLaps
Protein
LOINC Codes
- 41171-0 - Collagen CTx SerPl-mCnc
- 41171-0 - Collagen CTx SerPl-mCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.75 mL
Container
Plastic vial
Collection Instructions
Collect specimen prior to 10 a.m. Centrifuge and aliquot serum into plastic vial.
Patient Preparation
Fasting: 12 hours, required
Causes for Rejection
Gross hemolysis, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 72 hours |
| Frozen | 90 days |